Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants

Muhammed Olanrewaju Afolabi; Alfred B. Tiono; Uche J. Adetifa; Jean Baptiste Yaro; Abdoulie Drammeh; Issa Nébié; Carly M Bliss; Susanne H Hodgson; Nicholas A Anagnostou; Guillaume S. Sanou; Ya Jankey Jagne; Oumarou Ouedraogo; Casimir Tamara; Nicolas Ouedraogo; Mirielle Ouedraogo; Jainaba Njie-jobe; Amidou Diarra; Christopher J A Duncan; Riccardo Cortese; Alfredo L Nicosia; Rachel Roberts; Nicola K Viebig; Odile Leroy; Alison M Lawrie; Katie L. Flanagan; Beate Kampman; Philip A Bejon; Egeruan Babatunde Imoukhuede; Katie J Ewer; Adrian V S Hill; Kalifa Abubakr Bojang; Sodiomon B. Sirima

doi:10.1038/mt.2016.83

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants

Muhammed Olanrewaju Afolabi, Alfred B. Tiono, Uche J. Adetifa, Jean Baptiste Yaro, Abdoulie Drammeh, Issa Nébié, Carly M Bliss, Susanne H Hodgson, Nicholas A Anagnostou, Guillaume S. Sanou, Ya Jankey Jagne, Oumarou Ouedraogo, Casimir Tamara, Nicolas Ouedraogo, Mirielle Ouedraogo, Jainaba Njie-jobe, Amidou Diarra, Christopher J A Duncan, Riccardo Cortese, Alfredo L NicosiaRachel Roberts, Nicola K Viebig, Odile Leroy, Alison M Lawrie, Katie L. Flanagan, Beate Kampman, Philip A Bejon, Egeruan Babatunde Imoukhuede, Katie J Ewer, Adrian V S Hill, Kalifa Abubakr Bojang, Sodiomon B. Sirima

Immunology Alfred Hospital

Research output: Contribution to journal › Article › Research › peer-review

47 Citations (Scopus)

Abstract

Malaria remains a significant global health burden and a vaccine would make a substantial contribution to malaria control. Chimpanzee Adenovirus 63 Modified Vaccinia Ankara Multiple epitope thrombospondin adhesion protein (ME-TRAP) and vaccination has shown significant efficacy against malaria sporozoite challenge in malaria-naive European volunteers and against malaria infection in Kenyan adults. Infants are the target age group for malaria vaccination; however, no studies have yet assessed T-cell responses in children and infants. We enrolled 138 Gambian and Burkinabe children in four different age-groups: 2-6 years old in The Gambia; 5-17 months old in Burkina Faso; 5-12 months old, and also 10 weeks old, in The Gambia; and evaluated the safety and immunogenicity of Chimpanzee Adenovirus 63 Modified Vaccinia Ankara ME-TRAP heterologous prime-boost immunization. The vaccines were well tolerated in all age groups with no vaccine-related serious adverse events. T-cell responses to vaccination peaked 7 days after boosting with Modified Vaccinia Ankara, with T-cell responses highest in 10 week-old infants. Heterologous prime-boost immunization with Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara ME-TRAP was well tolerated in infants and children, inducing strong T-cell responses. We identify an approach that induces potent T-cell responses in infants, which may be useful for preventing other infectious diseases requiring cellular immunity.

Original language	English
Pages (from-to)	1470-1477
Number of pages	8
Journal	Molecular Therapy
Volume	24
Issue number	8
DOIs	https://doi.org/10.1038/mt.2016.83
Publication status	Published - 1 Aug 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/mt.2016.83

35731668-oaFinal published version, 164 KB

Cite this

Afolabi, M. O., Tiono, A. B., Adetifa, U. J., Yaro, J. B., Drammeh, A., Nébié, I., Bliss, C. M., Hodgson, S. H., Anagnostou, N. A., Sanou, G. S., Jagne, Y. J., Ouedraogo, O., Tamara, C., Ouedraogo, N., Ouedraogo, M., Njie-jobe, J., Diarra, A., Duncan, C. J. A., Cortese, R., ... Sirima, S. B. (2016). Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants. Molecular Therapy, 24(8), 1470-1477. https://doi.org/10.1038/mt.2016.83

@article{e76548ad6e7c4042b736f0ff1901d339,

title = "Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants",

abstract = "Malaria remains a significant global health burden and a vaccine would make a substantial contribution to malaria control. Chimpanzee Adenovirus 63 Modified Vaccinia Ankara Multiple epitope thrombospondin adhesion protein (ME-TRAP) and vaccination has shown significant efficacy against malaria sporozoite challenge in malaria-naive European volunteers and against malaria infection in Kenyan adults. Infants are the target age group for malaria vaccination; however, no studies have yet assessed T-cell responses in children and infants. We enrolled 138 Gambian and Burkinabe children in four different age-groups: 2-6 years old in The Gambia; 5-17 months old in Burkina Faso; 5-12 months old, and also 10 weeks old, in The Gambia; and evaluated the safety and immunogenicity of Chimpanzee Adenovirus 63 Modified Vaccinia Ankara ME-TRAP heterologous prime-boost immunization. The vaccines were well tolerated in all age groups with no vaccine-related serious adverse events. T-cell responses to vaccination peaked 7 days after boosting with Modified Vaccinia Ankara, with T-cell responses highest in 10 week-old infants. Heterologous prime-boost immunization with Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara ME-TRAP was well tolerated in infants and children, inducing strong T-cell responses. We identify an approach that induces potent T-cell responses in infants, which may be useful for preventing other infectious diseases requiring cellular immunity.",

author = "Afolabi, {Muhammed Olanrewaju} and Tiono, {Alfred B.} and Adetifa, {Uche J.} and Yaro, {Jean Baptiste} and Abdoulie Drammeh and Issa N{\'e}bi{\'e} and Bliss, {Carly M} and Hodgson, {Susanne H} and Anagnostou, {Nicholas A} and Sanou, {Guillaume S.} and Jagne, {Ya Jankey} and Oumarou Ouedraogo and Casimir Tamara and Nicolas Ouedraogo and Mirielle Ouedraogo and Jainaba Njie-jobe and Amidou Diarra and Duncan, {Christopher J A} and Riccardo Cortese and Nicosia, {Alfredo L} and Rachel Roberts and Viebig, {Nicola K} and Odile Leroy and Lawrie, {Alison M} and Flanagan, {Katie L.} and Beate Kampman and Bejon, {Philip A} and Imoukhuede, {Egeruan Babatunde} and Ewer, {Katie J} and Hill, {Adrian V S} and Bojang, {Kalifa Abubakr} and Sirima, {Sodiomon B.}",

year = "2016",

month = aug,

day = "1",

doi = "10.1038/mt.2016.83",

language = "English",

volume = "24",

pages = "1470--1477",

journal = "Molecular Therapy",

issn = "1525-0016",

publisher = "Cell Press",

number = "8",

}

Afolabi, MO, Tiono, AB, Adetifa, UJ, Yaro, JB, Drammeh, A, Nébié, I, Bliss, CM, Hodgson, SH, Anagnostou, NA, Sanou, GS, Jagne, YJ, Ouedraogo, O, Tamara, C, Ouedraogo, N, Ouedraogo, M, Njie-jobe, J, Diarra, A, Duncan, CJA, Cortese, R, Nicosia, AL, Roberts, R, Viebig, NK, Leroy, O, Lawrie, AM, Flanagan, KL, Kampman, B, Bejon, PA, Imoukhuede, EB, Ewer, KJ, Hill, AVS, Bojang, KA & Sirima, SB 2016, 'Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants', Molecular Therapy, vol. 24, no. 8, pp. 1470-1477. https://doi.org/10.1038/mt.2016.83

TY - JOUR

T1 - Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants

AU - Afolabi, Muhammed Olanrewaju

AU - Tiono, Alfred B.

AU - Adetifa, Uche J.

AU - Yaro, Jean Baptiste

AU - Drammeh, Abdoulie

AU - Nébié, Issa

AU - Bliss, Carly M

AU - Hodgson, Susanne H

AU - Anagnostou, Nicholas A

AU - Sanou, Guillaume S.

AU - Jagne, Ya Jankey

AU - Ouedraogo, Oumarou

AU - Tamara, Casimir

AU - Ouedraogo, Nicolas

AU - Ouedraogo, Mirielle

AU - Njie-jobe, Jainaba

AU - Diarra, Amidou

AU - Duncan, Christopher J A

AU - Cortese, Riccardo

AU - Nicosia, Alfredo L

AU - Roberts, Rachel

AU - Viebig, Nicola K

AU - Leroy, Odile

AU - Lawrie, Alison M

AU - Flanagan, Katie L.

AU - Kampman, Beate

AU - Bejon, Philip A

AU - Imoukhuede, Egeruan Babatunde

AU - Ewer, Katie J

AU - Hill, Adrian V S

AU - Bojang, Kalifa Abubakr

AU - Sirima, Sodiomon B.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Malaria remains a significant global health burden and a vaccine would make a substantial contribution to malaria control. Chimpanzee Adenovirus 63 Modified Vaccinia Ankara Multiple epitope thrombospondin adhesion protein (ME-TRAP) and vaccination has shown significant efficacy against malaria sporozoite challenge in malaria-naive European volunteers and against malaria infection in Kenyan adults. Infants are the target age group for malaria vaccination; however, no studies have yet assessed T-cell responses in children and infants. We enrolled 138 Gambian and Burkinabe children in four different age-groups: 2-6 years old in The Gambia; 5-17 months old in Burkina Faso; 5-12 months old, and also 10 weeks old, in The Gambia; and evaluated the safety and immunogenicity of Chimpanzee Adenovirus 63 Modified Vaccinia Ankara ME-TRAP heterologous prime-boost immunization. The vaccines were well tolerated in all age groups with no vaccine-related serious adverse events. T-cell responses to vaccination peaked 7 days after boosting with Modified Vaccinia Ankara, with T-cell responses highest in 10 week-old infants. Heterologous prime-boost immunization with Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara ME-TRAP was well tolerated in infants and children, inducing strong T-cell responses. We identify an approach that induces potent T-cell responses in infants, which may be useful for preventing other infectious diseases requiring cellular immunity.

AB - Malaria remains a significant global health burden and a vaccine would make a substantial contribution to malaria control. Chimpanzee Adenovirus 63 Modified Vaccinia Ankara Multiple epitope thrombospondin adhesion protein (ME-TRAP) and vaccination has shown significant efficacy against malaria sporozoite challenge in malaria-naive European volunteers and against malaria infection in Kenyan adults. Infants are the target age group for malaria vaccination; however, no studies have yet assessed T-cell responses in children and infants. We enrolled 138 Gambian and Burkinabe children in four different age-groups: 2-6 years old in The Gambia; 5-17 months old in Burkina Faso; 5-12 months old, and also 10 weeks old, in The Gambia; and evaluated the safety and immunogenicity of Chimpanzee Adenovirus 63 Modified Vaccinia Ankara ME-TRAP heterologous prime-boost immunization. The vaccines were well tolerated in all age groups with no vaccine-related serious adverse events. T-cell responses to vaccination peaked 7 days after boosting with Modified Vaccinia Ankara, with T-cell responses highest in 10 week-old infants. Heterologous prime-boost immunization with Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara ME-TRAP was well tolerated in infants and children, inducing strong T-cell responses. We identify an approach that induces potent T-cell responses in infants, which may be useful for preventing other infectious diseases requiring cellular immunity.

UR - http://www.scopus.com/inward/record.url?scp=84976353320&partnerID=8YFLogxK

U2 - 10.1038/mt.2016.83

DO - 10.1038/mt.2016.83

M3 - Article

AN - SCOPUS:84976353320

SN - 1525-0016

VL - 24

SP - 1470

EP - 1477

JO - Molecular Therapy

JF - Molecular Therapy

IS - 8

ER -

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants

Abstract

UN SDGs

Access to Document

Other files and links

Cite this